Skip to content

Research on integrated control protocols for influenza

Research on Integrated Prevention and Treatment of Infectious Diseases with Traditional Chinese Medicine

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000109
Enrollment
Unknown
Registered
2024-06-24
Start date
2024-07-01
Completion date
Unknown
Last updated
2024-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza A

Interventions

Chinese medicine combined with western medicine group:Astragalus and Huangqi Jiuwei Baidu decoction combined with oseltamivir phosphate capsule for the treatment of
Western medicine group:Ignore oseltamivir phosphate capsules
Chinese Medicines Group:Oral treatment with Huangqi Jiuwei Baidu Decoction

Sponsors

Guang'anmen Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Compliance with western medical diagnosis of influenza A; (2) Comply with the Chinese medicine diagnostic criteria for the syndrome of surface cold and internal heat; (3) Age between 18-70 years old, gender is not limited; 4) Onset time = 48h; (5) Body temperature =37.3?; (6) Willing to participate in the study and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1) Patients with severe influenza, critically ill influenza, or influenza viral pneumonia; 2) Combined bacterial, fungal, or other respiratory viral (e.g., respiratory syncytial virus, rhinovirus, etc.) infection Patients; (3) Patients with combined serious primary diseases of the lung, heart, brain, liver, kidney and other systems; (4) Pregnant or breastfeeding women and women who plan to become pregnant during the study period; (5) Known allergy to the components of the research product, or allergy; 6) Patients with psychiatric abnormalities who cannot cooperate with the study, or patients with epilepsy with unstable conditions; 7) Those who have been treated with anti-viral medications prior to the visit; (8) Those who have other inappropriate drug test observation, or cannot cooperate with the treatment, and it is difficult to make a definitive evaluation of the effectiveness and safety of the drug. The patients who are not able to cooperate with the treatment, and it is difficult to make a definite evaluation of the effectiveness and safety of the drugs.

Design outcomes

Primary

MeasureTime frame
Antigen conversion time/rate;

Secondary

MeasureTime frame
Chinese Medicine Score;Serological indicators;Pre- and post-treatment tongue image;

Countries

China

Contacts

Public ContactWenliang Lv

Guang'anmen Hospital

lvwenliang@sohu.com18601237779

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026